Technical Analysis for CGEN - Compugen Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 4.90% | |
| Lower Bollinger Band Walk | Weakness | 4.90% | |
| Oversold Stochastic | Weakness | 4.90% | |
| Stochastic Buy Signal | Bullish | 4.17% | |
| Calm After Storm | Range Contraction | 4.17% | |
| Lower Bollinger Band Walk | Weakness | 4.17% | |
| Lower Bollinger Band Touch | Weakness | 4.17% | |
| Oversold Stochastic | Weakness | 4.17% | |
| Calm After Storm | Range Contraction | 4.90% | |
| Lower Bollinger Band Walk | Weakness | 4.90% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 1 hour ago |
| Up 5% | about 1 hour ago |
| Up 3% | about 1 hour ago |
| Up 2% | about 2 hours ago |
| Up 1% | about 2 hours ago |
Get a Trading Sidekick!
- Earnings date: 11/12/2024
Compugen Ltd. Description
Compugen Ltd., a therapeutic product discovery company, engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates primarily in the United States, Europe, and Israel. It focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. The company's therapeutic proteins pipeline includes CGEN-15001, a novel protein for the treatment of autoimmune disorders; CGEN-15021, a novel fusion protein for the treatment of multiple sclerosis, rheumatoid arthritis, and other autoimmune diseases; CGEN-15091, a novel fusion protein for the treatment of multiple sclerosis and autoimmune diseases; CGEN-15031, a fusion protein candidate to treat multiple sclerosis; and CGEN-15051, a fusion protein candidate for the treatment of rheumatoid arthritis. Its monoclonal antibody therapy product candidates include CGEN-15001T, a membrane protein target for the treatment of cancer; CGEN-15022 membrane protein for the treatment of multiple cancers; CGEN-671, a novel drug target for the treatment of multiple epithelial tumors; and CGEN-928 drug target for the treatment of multiple myeloma. Compugen Ltd. was founded in 1993 and is headquartered in Tel Aviv, Israel.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Life Sciences Immunology Autoimmune Disease Antibodies Treatment Of Cancer Monoclonal Antibodies Monoclonal Antibody Antibody Therapeutic Products Biomarkers Autoimmunity Multiple Sclerosis Rheumatoid Arthritis Multiple Myeloma Autoimmune Disorders Immune Disorders Fusion Protein Compugen Monoclonal Antibody Therapy Treatment Of Multiple Sclerosis Antibody Therapy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.0301 |
| 52 Week Low | 0.62 |
| Average Volume | 229,656 |
| 200-Day Moving Average | 2.01 |
| 50-Day Moving Average | 1.72 |
| 20-Day Moving Average | 1.62 |
| 10-Day Moving Average | 1.57 |
| Average True Range | 0.10 |
| RSI (14) | 33.33 |
| ADX | 20.87 |
| +DI | 16.24 |
| -DI | 29.95 |
| Chandelier Exit (Long, 3 ATRs) | 1.56 |
| Chandelier Exit (Short, 3 ATRs) | 1.64 |
| Upper Bollinger Bands | 1.86 |
| Lower Bollinger Band | 1.38 |
| Percent B (%b) | 0.1 |
| BandWidth | 29.50 |
| MACD Line | -0.08 |
| MACD Signal Line | -0.05 |
| MACD Histogram | -0.0255 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.56 | ||||
| Resistance 3 (R3) | 1.56 | 1.53 | 1.54 | ||
| Resistance 2 (R2) | 1.53 | 1.49 | 1.52 | 1.53 | |
| Resistance 1 (R1) | 1.48 | 1.47 | 1.46 | 1.47 | 1.52 |
| Pivot Point | 1.44 | 1.44 | 1.43 | 1.44 | 1.44 |
| Support 1 (S1) | 1.39 | 1.41 | 1.38 | 1.39 | 1.34 |
| Support 2 (S2) | 1.36 | 1.39 | 1.35 | 1.33 | |
| Support 3 (S3) | 1.31 | 1.36 | 1.32 | ||
| Support 4 (S4) | 1.30 |
